Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Importance Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase
(ALK), has shown systemic and central nervous system efficacy for patients withALK-positive …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Pancreatic ductal adenocarcinoma (PDAC) patients have a 5-year survival rate of only 8%
largely due to late diagnosis and insufficient therapeutic options. Neutrophils are among the …

Highlights•Understanding mechanisms of resistance in oncogene-driven lung cancer is
crucial.•MET amplification is a recurrent driver of resistance, across molecularly defined …

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-
small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on …

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …